John Oyler, Endpoints

BeiGene lines up its first shot at crack­ing the megablock­buster PD-1 mar­ket for lung can­cer. But can they over­come un­der­dog sta­tus?

BeiGene took an­oth­er big step to­wards chal­leng­ing Mer­ck, Bris­tol-My­ers Squibb, As­traZeneca and some oth­er Big Phar­ma heavy­weights for a share of the lu­cra­tive lung can­cer mar­ket for the PD-(L)1s rack­ing up bil­lions in an­nu­al rev­enue.

The Chi­na-based biotech $BGNE run by CEO John Oyler post­ed pos­i­tive top-line pro­gres­sion-free sur­vival re­sults for their piv­otal Chi­nese study on their PD-1 an­ti­body tislelizum­ab com­bined with chemo for squa­mous non-small cell lung can­cer in front­line cas­es. Squa­mous NSCLC ac­counts for about 30% of the over­all lung can­cer mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.